Key result
(P)RR immunoreactivity was detected in 72% of breast carcinoma cases and was significantly associated with higher cancer cell proliferation, as indicated by a greater number of (P)RR-positive cases in the Ki-67 ≥ 10% group (P = 0.02).
Observational (n=69)
No
p-value: p=0.02
The (pro)renin receptor is expressed in human breast carcinomas and its blockade inhibits cancer cell proliferation, suggesting a potential novel therapeutic target.
Hypothesis-generating for (P)RR blockade in breast cancer; should not yet change clinical practice.
(Pro)renin receptor ((P)RR) is a specific receptor for renin and prorenin. The aim of the present study is to clarify expression of (P)RR and pathophysiological roles of (P)RR in human breast carcinomas. (P)RR expression was studied in 69 clinical cases of breast carcinoma by immunohistochemistry.Effects of (P)RR on cell proliferation were examined in cultured human breast carcinoma cells using (P)RR specific small interference RNA. Immunohistochemistry showed that(P)RR immunoreactivity was detected in the breast carcinoma cells in 50 of 69 cases of breast carcinoma (72%). The analysis on association between (P)RR immunoreactivity and clinicopathological parameters showed that the number of (P)RR positive cases was significantly greater in Ki-67 (a cell proliferation marker)≥10% group than in Ki-67<10% group (P=0.02). (P)RR was expressed in 4 types of human breast carcinoma cell lines. (P)RR specific small interference RNA inhibited proliferation of both MCF-7 (ERα positive) and SK-BR-3 (ERα negative) cells. The present study has shown, for the first time, the expression of (P)RR in human breast carcinoma tissues and cultured breast carcinoma cell lines. These findings have raised the possibility that the blockade of the (P)RR signaling may be a novel therapeutic strategy against breast carcinomas.
No takes yet. Share an insight, caveat, or question.
Ohba et al. (2014) conducted an observational in Breast carcinoma (n=69). (pro)renin receptor ((P)RR) expression vs. (P)RR negative expression was evaluated on Association between (P)RR immunoreactivity and Ki-67 cell proliferation marker status (≥ 10% vs < 10%) (p=0.02). (P)RR immunoreactivity was detected in 72% of breast carcinoma cases and was significantly associated with higher cancer cell proliferation, as indicated by a greater number of (P)RR-positive cases in the Ki-67 ≥ 10% group (P = 0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: